Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.84 |
| ▸ | KDR | P35968 | 2/20 | 0.84 |
| ▸ | AURKA | O14965 | 1/20 | 0.84 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.84 |
| ▸ | INSR | P06213 | 1/20 | 0.84 |
| ▸ | FBP1 | P09467 | 1/20 | 0.84 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.84 |
| ▸ | FLT4 | P35916 | 1/20 | 0.84 |
| ▸ | CLK1 | P49759 | 1/20 | 0.84 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.84 |
| ▸ | TEK | Q02763 | 1/20 | 0.84 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28907231 | 1.00 | EGFR (0.84) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL28520911 | 0.96 | EGFR (0.85) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL14964773 | 0.96 | EGFR (0.85) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL30207668 | 0.96 | EGFR (0.85) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL31491085 | 0.96 | EGFR (0.85) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL29577645 | 0.95 | FBP1 (0.78) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL30520472 | 0.93 | EGFR (0.87) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL13524614 | 0.93 | EGFR (0.87) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL14863005 | 0.92 | EGFR (0.84) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL14092460 | 0.92 | EGFR (0.92) | EGFRKDRAURKAERBB2INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106892898-B | Azasugar-derived quinazolines | 陕西师范大学 | 2021-02-05 | — | — | CN | disclosed |
| US-7196091-B2 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-27 | — | — | US | disclosed |
| US-20060264450-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | HIMMELSBACH FRANK | 2006-11-23 | — | — | US | disclosed |
| EP-1641767-A2 | BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR PREPARING THE SAME | Boehringer Ingelheim International GmbH (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-20050014772-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108664-A2 | BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR PREPARING THE SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014772-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | RET, CYP11B1, CYP11B2 | EGFR 471/4885KDR 1302/4885AURKA 332/4885 |
| US-20060264450-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | RET, CYP11B1, CYP11B2 | EGFR 471/4885KDR 1302/4885AURKA 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.